Repair and regeneration of ocular tissue using postpartum-derived cells
Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of ocular tissue using the postpartum-derived cells are also disclosed.
1. A method for promoting axonal regeneration in an optic nerve in a patient having optic nerve trauma comprising administering to the optic nerve isolated umbilicus-derived cells isolated from human umbilical cord tissue substantially free of blood, in an amount effective to promote axonal regeneration, wherein the isolated umbilicus-derived cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, maintain a normal karyotype upon passaging and lack production of CD117.
2. The method of claim 1 , wherein the isolated umbilicus-derived cells further have the following characteristics:
a) potential for at least 40 population doublings in culture;
b) production of CD10, CD13, CD44, CD73, and CD90;
c) lack of production of CD31, CD34, CD45, and CD141; and
d) increased expression of genes encoding interleukin 8 and reticulon 1 relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell.
3. The method of claim 2 , wherein the isolated umbilicus-derived cells are positive for HLA-A,B,C, and negative for HLA-DR,DP,DQ.
4. The method of claim 1 , wherein the isolated umbilicus-derived cells are expanded in culture prior to administering to the optic nerve.
5. The method of claim 1 , wherein the isolated umbilicus-derived cells are administered with at least one other agent.
6. The method of claim 5 , wherein the at least one other agent is administered simultaneously with, or before, or after, the isolated umbilicus-derived cells.
7. The method of claim 1 , wherein the isolated umbilicus-derived cells are administered through a cannula or from a device inserted in the patient's eye.
8. The method of claim 1 , wherein the isolated umbilicus-derived cells are administered by insertion of a matrix or scaffold containing the cells.
9. A method for preserving the outer nuclear layer of a retina in a patient with retinal degeneration comprising administering to the interior of the patient's eye isolated umbilicus-derived cells isolated from human umbilical cord tissue substantially free of blood, in an amount effective to preserve the outer nuclear layer, wherein the isolated umbilicus-derived cells are capable of self-renewal and expansion in culture, have the potential to differentiate into cells of at least a neural phenotype, maintain a normal karyotype upon passaging and lack production of CD117.
10. The method of claim 9 , wherein the isolated umbilicus-derived cells further have the following characteristics:
a) potential for at least 40 population doublings in culture;
b) production of CD10, CD13, CD44, CD73, and CD90;
c) lack of production of CD31, CD34, CD45, and CD141; and
d) increased expression of genes encoding interleukin 8 and reticulon 1 relative to a human cell that is a fibroblast, a mesenchymal stem cell, or an iliac crest bone marrow cell.
11. The method of claim 10 , wherein the isolated umbilicus-derived cells are positive for HLA-A,B,C, and negative for HLA-DR,DP,DQ.
12. The method of claim 9 , wherein the isolated umbilicus-derived cells are expanded in culture prior to administering to the interior of the patient's eye.
13. The method of claim 9 , wherein the isolated umbilicus-derived cells are administered with at least one other agent.
14. The method of claim 13 , wherein the at least one other agent is administered simultaneously with, or before, or after, the isolated umbilicus-derived cells.
15. The method of claim 9 , wherein the isolated umbilicus-derived cells are administered through a cannula or from a device inserted in the patient's eye.
16. The method of claim 9 , wherein the isolated umbilicus-derived cells are administered by insertion of a matrix or scaffold containing the cells.